GRAIL, Inc.

Company Overview

GRAIL, Inc. (NASDAQ: GRAL) is a healthcare and biotechnology company focused on early cancer detection through blood-based screening technologies. The company operates within the oncology diagnostics and precision medicine industries, with its primary commercial product being the Galleri multi-cancer early detection (MCED) test. Galleri is designed to detect signals associated with multiple types of cancer from a single blood draw, including cancers that currently lack recommended screening protocols. GRAIL generates revenue primarily through test sales, healthcare partnerships, and research collaborations related to genomic medicine and cancer detection technologies.

The company was founded in 2016 as a spinout from Illumina, Inc., leveraging advances in next-generation sequencing and machine learning to develop population-scale cancer screening tools. Illumina acquired GRAIL in 2021, but following regulatory challenges involving U.S. and European antitrust authorities, GRAIL was spun back out as an independent public company in 2024. GRAIL’s strategic positioning is centered on combining large-scale genomic datasets, proprietary methylation analysis, and artificial intelligence-driven classification models to identify cancer signals at earlier stages than conventional diagnostic approaches.